Orphazyme AS (CHIX:ORPHAC) Short-Term Debt : kr0.00 Mil (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Short-Term Debt?

Orphazyme AS's Short-Term Debt for the quarter that ended in Jun. 2022 was kr0.00 Mil.

Orphazyme AS's quarterly Short-Term Debt declined from Jun. 2021 (kr33.93 Mil) to Dec. 2021 (kr30.98 Mil) and declined from Dec. 2021 (kr30.98 Mil) to Jun. 2022 (kr0.00 Mil).

Orphazyme AS's annual Short-Term Debt increased from Dec. 2019 (kr12.81 Mil) to Dec. 2020 (kr33.35 Mil) but then declined from Dec. 2020 (kr33.35 Mil) to Dec. 2021 (kr30.98 Mil).

Orphazyme AS Short-Term Debt Historical Data

The historical data trend for Orphazyme AS's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Short-Term Debt Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Short-Term Debt

Get a 7-Day Free Trial

12.81

33.35

30.98

Orphazyme AS Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Short-Term Debt	Get a 7-Day Free Trial									29.95	33.35	33.93	30.98	-

Orphazyme AS Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Orphazyme AS Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS Headlines

No Headlines